COMPANY PROFILE

Nuvectis

Innovative biopharmaceuticals targeting cancer with novel oral small molecule inhibitors

Fort Lee, United StatesBiotech & Life Sciences

Valuation $664M Market cap · 2026

About Nuvectis

Nuvectis Pharma, Inc. is a biopharmaceutical company specializing in the development of targeted therapies for cancer treatment. The company focuses on creating novel oral small molecule inhibitors, specifically NXP800 and NXP900, which target the HSF1 pathway and SRC YES1 kinase, respectively. Nuvectis serves patients with ovarian clear cell carcinoma (OCCC) and advanced stage endometrioid ovarian cancer. Founded in 2020, the company operates in the oncology market and leverages its expertise in target selection, drug profiling, and clinical and regulatory execution to build its pipeline. Nuvectis generates revenue through the development and potential commercialization of its drug candidates. The company is led by a team of industry veterans with extensive experience in drug development and regulatory success.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Headquarters: Fort Lee, United States
Listing: IPO 2022
Employees: 5
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITY✓Other financing	Jul 2026	$115M	—	Tang Capital · Sphera Funds Management · Polus Capital · Soleus Capital	↗
POST IPO EQUITY✓Other financing	May 2025	$60M	—	Undisclosed	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$0	—	−$28M	—	−$26M	—	$18M
2025	$0	—	−$28M	—	−$26M	—	$18M
2024	$0	—	−$20M	—	−$19M	—	$13M
2023	$0	—	−$23M	—		—	$15M
2022	$0	—	−$19M	—		—
2021	—	—	−$13M	—		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Nuvectis website traffic

Latest recorded traffic for Nuvectis is 5.2K monthly website visits, up 881.1% over the last three months.

Latest monthly visits5.2K 3-month web change+881.1%

Monthly website visitsJan 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VOVodorasloYour solution to better air quality	Sofia, Bulgaria	Operational	1	$61K	$132K
NBNormax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness	Cork, Ireland	Operational
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational
LTLTZ TherapeuticsDevelops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need	Redwood City, United States	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
RPRivus PharmaceuticalsOperates as a biopharmaceutical company dedicated to improving cardio-metabolic health	Charlottesville, United States	Operational
KTKintsugi TherapeuticsDevelopment of ER stress inhibitors for the treatment of metabolic diseases	Barcelona, Spain	Operational